Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.40 |
| ▸ | FEN1 | P39748 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526574 | 0.93 | G6PD (0.51) | HRH4G6PDIDEPTGS2KDM1A | |
| SCHEMBL20526514 | 0.84 | HRH4 (0.53) | HRH4 | |
| SCHEMBL20526498 | 0.83 | SLC6A2 (0.43) | HRH4PTGS2ALOX5APFEN1 | |
| SCHEMBL23361329 | 0.82 | PTGS2 (0.52) | HRH4G6PDIDEPTGS2ALOX5AP | |
| SCHEMBL20526579 | 0.80 | ALDH1A1 (0.58) | HRH4PTGS2ALOX5APFEN1 | |
| SCHEMBL20526563 | 0.78 | HTT (0.54) | HRH4 | |
| SCHEMBL20526559 | 0.77 | HRH4 (0.51) | HRH4 | |
| SCHEMBL20339551 | 0.72 | HRH4 (0.39) | HRH4G6PDIDEPTGS2 | |
| SCHEMBL8662752 | 0.72 | CHRNB2 (0.41) | ALOX5APFEN1 | |
| SCHEMBL898422 | 0.72 | G6PD (0.64) | G6PDIDEHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-08 | — | — | US | disclosed |
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-08 | — | — | US | disclosed |
| WO-2018187652-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | WO | disclosed |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | HRH4, HRH3, HRH2 | HRH4 1/4885G6PD 2043/4885IDE 3480/4885 |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | HRH4, HRH3, HRH2 | HRH4 1/4885G6PD 2043/4885IDE 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.